Track topics on Twitter Track topics that are important to you
According to Zacks, "Mylan's EpiPen woes continues as sales of the product declined due to increased competition and entry of generics. Pricing continues to impact results and the company projects mid-single digit price erosion globally for the year.
Original Article: Mylan N.V. (MYL) Upgraded by Zacks Investment Research to HoldNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...